Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13672294 | 1.00 | F10 (0.42) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL4484924 | 1.00 | F10 (0.42) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL4479109 | 0.89 | F10 (0.47) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL13675125 | 0.87 | F10 (0.39) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL4485110 | 0.87 | F10 (0.54) | F10ABCB11F2ST14 | |
| SCHEMBL13672264 | 0.87 | F10 (0.54) | F10ABCB11F2ST14 | |
| SCHEMBL4485107 | 0.87 | F10 (0.54) | F10ABCB11F2ST14 | |
| SCHEMBL13672293 | 0.84 | F10 (0.53) | F10 | |
| SCHEMBL4492161 | 0.84 | F10 (0.53) | F10 | |
| SCHEMBL4492159 | 0.84 | F10 (0.53) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601752-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1951717-A1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF COAGULATION FACTOR XA | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007057317-A1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF COAGULATION FACTOR XA | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-24 | — | — | WO | disclosed |
| US-20070112001-A1 | Pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112001-A1 | Pyrrolidine derivatives | F12, F2, F11 | F10 7/4885ABCB11 798/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.